Use Of Ryoncil First Line After Steroids For Pediatric Acute Graft Versus Host Disease Highlighted In Key Opinion Leader Webinar
Mesoblast hosted a key opinion leader webinar featuring pediatric transplant specialist Dr. Susan Prockop on use of Ryoncil first line after steroids in pediatric acute graft-versus-host disease. Dr. Prockop presented case studies and pivotal trial results supporting Ryoncil as a new treatment paradigm beyond its approved steroid-refractory pediatric aGvHD indication.
Key figures
- Patents
- over 1,000 granted patents or patent applications
- Ip protection through
- 2044
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.